About: Infections after T‐replete haploidentical transplantation and high‐dose cyclophosphamide as graft‐versus‐host disease prophylaxis

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Infections after T‐replete haploidentical transplantation and high‐dose cyclophosphamide as graft‐versus‐host disease prophylaxis Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
title	Infections after T‐replete haploidentical transplantation and high‐dose cyclophosphamide as graft‐versus‐host disease prophylaxis
Creator	Bramanti, S Carlo-Stella, C Casari, E Castagna, L Crocchiolo, R Crocchiolo, Roberto Lugli, E Mauro, E Mavilio, D Mineri, R Santoro, A Sarina, B Timofeeva, I Tordato, F Vai, A
source	PMC
abstract	BACKGROUND: Recently, a platform of T‐cell replete haploidentical hematopoietic stem cell transplantation (haplo‐HSCT) using post‐transplant cyclophosphamide (Cy) has shown high reproducibility and acceptable safety profile. METHOD: This prospective cohort analysis allowed us to collect data on infections among 70 consecutive recipients of haplo‐HSCT affected by various hematologic malignancies. RESULTS: After a median follow‐up of 23 months, cumulative incidence of viral infections was 70% (95% confidence interval [CI] 59–81) at 100 days and 77% (95% CI 67–87) at 1 year; 35 of 65 patients at risk had CMV reactivation (54%) and the rate of polyomavirus‐virus‐associated cystitis was 19% (13/70). Cumulative incidence of bacterial and fungal infections at 1 year were 63% (95% CI 51–75) and 12% (95% CI 4–19), respectively. Of note, only 1 invasive fungal infection occurred beyond 1 year after transplant (day +739). CONCLUSION: In conclusion, despite a high rate of viral infections in the early period, present data suggest a satisfactory infectious profile after T‐cell replete haplo‐HSCT using post‐transplant Cy. These results may help clinicians to improve both prophylactic and therapeutic antimicrobial strategies in this emerging haploidentical setting.
has issue date	2015-03-26(xsd:dateTime)
bibo:doi	10.1111/tid.12365
bibo:pmid	25648539
has license	no-cc
sha1sum (hex)	dd021d5e3273bad9458f4deb31f878632a5e624f
schema:url	https://doi.org/10.1111/tid.12365
resource representing a document's title	Infections after T‐replete haploidentical transplantation and high‐dose cyclophosphamide as graft‐versus‐host disease prophylaxis
has PubMed Central identifier	PMC7169814
has PubMed identifier	25648539
schema:publication	Transpl Infect Dis
resource representing a document's body	covid:dd021d5e3273bad9458f4deb31f878632a5e624f#body_text
is schema:about of	named entity 'graft-versus-host disease' named entity 'platform' named entity 'T-cell' named entity 'All rights reserved' named entity 'transplantation' named entity 'hematopoietic stem cell' named entity 'prophylaxis' named entity 'hematopoietic stem cell transplantation' named entity 'reproducibility' named entity 'graft-versus-host disease' named entity 'high-dose' named entity 'pneumonia' named entity 'pneumonia' named entity 'hematologic malignancies' named entity 'candidiasis' named entity 'primary antibody' named entity 'CD3' named entity 'stem cells' named entity 'CMV' named entity 'kidney' named entity 'esophageal cancer' named entity 'tacrolimus' named entity 'HSCT' named entity 'Candida' named entity 'pathogen' named entity 'GVHD' named entity 'cidofovir' named entity 'relapse' named entity 'infusion' named entity 'echinocandin' named entity 'toxicity' named entity '10.8' named entity 'median follow-up' named entity 'Conditioning regimens' named entity 'bacterial pneumonia' named entity 'CD56' named entity 'progressive multifocal leukoencephalopathy' named entity 'levofloxacin' named entity 'CMV' named entity 'empirical therapy' named entity 'cyclosporine' named entity 'Logrank test' named entity 'CMV' named entity 'CMV' named entity 'pneumonia' named entity 'Italy' named entity 'memory cells' named entity 'autologous' named entity 'T-cell' named entity 'CMV' named entity 'GVHD' named entity 'Neutrophil' named entity 'pneumonia' named entity 'ganciclovir' named entity 'Beckman Coulter' named entity 'thiotepa' named entity 'TBI' named entity 'bacterial infections' named entity 'prophylaxis' named entity 'intravenous' named entity 'HSCT' named entity 'invasive candidiasis' named entity 'cyclosporine' named entity 'pneumonia' named entity 'risk factor' named entity 'aminoglycoside' named entity 'candidemia'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software